Clinical trial
Dasatinib in Resectable Malignant Pleural Mesothelioma
NCT00652574
Study timeline
Study start (actual)2008-03-12Date precision: day
Registry last updated2022-10-31
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Malignant Pleural Mesotheliomaunresolved
Interventions
DasatinibDRUG · verified · RxNorm: dasatinib
Sponsors & collaborators
M.D. Anderson Cancer Centerlead sponsor
Bristol-Myers Squibbcollaborator
United States Department of Defensecollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00652574 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.